Date: 2018-01-03
Type of information: Nomination
Compound: chief medical officer
Company: Boston Pharmaceuticals (USA - MA)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On January 3, 2018, Boston Pharmaceuticals announced the appointment of Peter Ho as Chief Medical Officer. Dr. Ho joins Boston Pharmaceuticals from Epizyme, where as Chief Medical Officer he led the company’s clinical development, translational medicine and regulatory affairs functions. At Boston Pharmaceuticals, Dr. Ho will oversee the clinical development the company’s diversified portfolio of candidates. Prior to joining Epizyme, Dr. Ho was co-founder and president of BeiGene Ltd. His previous pharmaceutical positions included vice president of Oncology Clinical Development at Johnson and Johnson and senior vice president of the Oncology Center of Excellence in Drug Discovery at GSK. Dr. Ho began his career in drug discovery and development at the Investigational Drug Branch of the Cancer Therapy Evaluation Program, National Cancer
Institute (NCI) followed by positions of increasing responsibility at Novartis and DuPont Pharmaceuticals.
- Over his career, Dr. Ho has been directly responsible for first-in-human dosing of 17 anticancer agents and has overseen the development of over 50 hematology and oncology compounds. His work has contributed to seven new chemical entity approvals to-date including Gleevec®, Arranon®, Tykerb®, Promacta®, Votrient®, Tafinlar® and Mekinist® (all trademarks registered to Novartis). Dr. Ho completed his pediatrics residency at The Children's Hospital of Boston
followed by clinical fellowships in pediatric hematology/oncology at the Dana-Farber Cancer
Institute and in clinical oncology and regulatory sciences jointly through the FDA and the NCI. He received a BA in biology from The Johns Hopkins University, and MD and PhD degrees from Yale University.
- Dr. Ho serves on the Scientific Advisory Board of Accent Therapeutics and served as a member of the Pediatric Cancer
Working Group of the Cancer Moonshot Task Force.
Financial terms:
Latest news:
Is general: Yes
